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A psychiatric core laboratory was responsible for patient safety and for centralized training in the standardized application of all psychometric instruments employed during the study. Prior to participating in MOOD-HF, all psychiatrists and psychosomatic specialists underwent standardized Structured Clinical Interview (SCID) training and all cardiologists underwent standardized Montgomery-Åsberg Depression Rating Scale (MADRS) training at the MOOD-HF psychiatric core laboratory. Furthermore, specialized nurses received centralized standardized training in the monitoring of depressive symptoms by telephone (especially the discrimination between suicidal ideation and mere tiredness of life) and in the supervision of cardiac status, up-titration of heart failure medications (in collaboration with the patients' cardiologist and primary care physician) and patient empowerment. Study results were analyzed at the Institute of Clinical Epidemiology and Biometry of Würzburg University, Würzburg, Germany.
Inclusion and exclusion criteria
Patients were eligible for inclusion in the MOOD-HF trial if they met all of the following inclusion criteria:  Age ≥18 years.  Chronic systolic heart failure of any etiology (current New York Heart Association [NYHA] class II-IV) and at least one left ventricular ejection fraction (LVEF) measurement of less than 45% obtained by echocardiography, levocardiography or cardiac magnet resonance imaging within the preceding three months.  Diagnostic and Statistical Manual of Mental Disorders-IV diagnosis of current major depression based on the Structured Clinical Interview for DSM-IV performed by a certified psychiatric/psychosomatic specialist.  Provision of written informed consent.
Patients with any of the following were excluded from the MOOD-HF trial:  Recent history of acute myocardial infarction (<3 months).  Acute cardiac decompensation.  Recent (<3 months) or planned major cardiac surgery (<12 months).  Advanced renal failure (Modification of Diet in Renal Disease [MDRD] <30 mL/min/1.73m²).  Moderate or severe hepatic insufficiency (plasma level of serum transaminases more than three times the upper limit of normal) or manifest hepatic failure.  Thyrotoxicosis.  Other medical contraindications to treatment with selective serotonin re-uptake inhibitors (SSRIs).  Significantly reduced life expectancy due to other comorbidity (e.g. malignancy).  Use of any antidepressants including SSRIs, lithium or anticonvulsants for mood disorder in adequate dosage (according to evidence-based recommendations for clinical effectiveness), with sufficiently long duration (at least 8 weeks) of antidepressant treatment and positive clinical outcome*.  Currently undergoing any form of psychotherapy.  Absence of response to a previous adequate trial of escitalopram treatment.  Lifetime history of early termination (<8 weeks) of escitalopram treatment because of adverse events or side effects.  Lifetime history of early termination (<8 weeks) of other SSRI (e.g. sertraline, citalopram) treatment because of adverse events or side effects.  Bipolar affective disorder documented by Structured Clinical Interview (SCID).
 Severe depressive episode with psychotic features.  Evidence of substance abuse or dependency during the previous 12 months.  Moderate or severe dementia (Mini-Mental State Examination [MMSE] score <18).  Serious risk of imminent suicide based on clinical judgment.  Participation in another clinical trial.  Inability to comply with nine-item Patient Health Questionnaire (PHQ-9) and/or SCID testing and/or telephone monitoring for mental or linguistic reasons or lack of access to a telephone.  Pregnancy or nursing period.  Women of child-bearing potential without effective contraception during the trial.  Expected low compliance with the visit schedule or telephone monitoring (e.g. due to comorbidity or travel distance to the trial site).  Patients with normal ventricular activation (no bundle branch block [total or incomplete], no other intraventricular conduction delay, and no pacemaker) and known QTc** prolongation ≥500 msec or known long QT syndrome***  Current treatment with drugs inducing QT prolongation, such as class IA and class III antiarrhythmic drugs, anti-psychotics, and tricyclic antidepressants.
*Patients already on antidepressants were assessed carefully because the "use of any antidepressants" was only an exclusion criterion in cases who (a) followed a treatment regimen initiated by a psychiatrist, and (b) who had been receiving an antidepressant(s) for at least 8 weeks and at sufficient dosages (according to evidence-based recommendations for clinical effectiveness) to justify anticipation of a beneficial clinical effect. It is not uncommon that patients receive antidepressants for a prolonged period of time, but continue to show depressive symptoms even at adequate drug dosages. Non-response to treatment might be the result of insufficient dosage, lack of response to the antidepressant or lack of adequate psychiatric care. For example, a patient with symptomatic heart failure received 20 mg/day amitriptyline over a period of two years. No clinical benefit was observed. The patient had never been seen by a psychiatrist. When evaluated for MOOD-HF the patient scored >11 on the PHQ-9 assessment. In this case the dosage of the tricyclic antidepressant amitriptyline could not be increased because of potential cardiotoxicity, and the under-dosed, ineffective amitriptyline therapy could be stopped. Under these circumstances, "use of any antidepressants" did no longer represent an exclusion criterion. This patient could be included in MOOD-HF, and receive optimal heart failure therapy plus potentially effective antidepressant treatment. In unclear cases, a member of the Psychiatric Core Lab needed to be contacted before a patient was denied study participation or openlabel antidepressant therapy was started. **QTc is defined as QT interval/square root RR interval (QTc = QT-time/√RR-Interval) according to Bazett. ***Patients with prolonged QRS duration due to bundle branch block or other intraventricular conduction delay or with a pacemaker could be enrolled into MOOD-HF with QTc intervals >500 msec.
Randomization and stratification
Randomization was 1:1 to either escitalopram or placebo. The randomization routine used Pocock's minimization algorithm. 1 Stratification was performed for the following factors:  Gender (male/female)  Age (<70 years versus ≥70 years)  Severity of depression (PHQ score ≤16 versus >16).  Time elapsed since the last hospital discharge (≤4 weeks versus >4 weeks).
Sample size calculation
According to a previous study, 2 and based on data available to the authors in the frame of the Competence Network Heart Failure 3 from recently completed or ongoing clinical studies at the time MOOD-HF was designed, a 45% annual event rate for the composite endpoint of morbidity and mortality was assumed during the natural clinical course in our target population, which we expected to consist of a heterogeneous sample of patients with chronic heart failure, with or without recent previous hospitalization for heart failure.
We pragmatically assumed a 20% relative reduction of the composite primary outcome by study participation per se (due to enhanced heart failure care leading to optimization of heart failure therapy and improved medication adherence). Thus, in the placebo group the expected event rate was 36%. Given that the event rate in depressed versus non-depressed patients has been reported to be >2-fold higher, 2,4,5 it was estimated that 18% of primary endpoint events could potentially be attributable to depression. We assumed that escitalopram might (by reducing depression) reduce the annual depression-related event rate by 50% in the intervention group, assuming that at least half of all patients would respond to the treatment. Observation periods for the first and last patients were planned to be 24 and 12 months, respectively. The annual dropout rate was assumed to be 15%. Thus, the assumption for effect size was a cumulative event rate of 27% in the escitalopram group versus 36% in the placebo group, corresponding to a hazard ratio of ln(0.73)/ln(0.64) = 0.705. Accordingly, setting the type I error level at 5% and the power to detect a difference in event rates at 80%, a total of [2 x (1.96+0.84)/ln(0.705)] 2 = 257 endpoint events confirmed by the independent endpoint committee were needed. A sample size of 700 patients (350 per study arm) was assumed to be sufficient to provide this number of primary outcome events (all-cause death or allcause hospitalization with the exception of pre-planned hospital admission for non-cardiac reasons).
After recruitment of 240 patients who, by January 31, 2012, had spent 138 patient-years at risk and under observation in the study, a total of 115 primary outcome events had been recorded, and the Kaplan-Meier estimate of the overall annual event rate amounted to 60% (higher than the anticipated average event rate of 31.5%). Taking into account the remaining time under observation and the dropout rate for patients already recruited, it could be expected that these patients would contribute another 55 events. In accordance with the assumption (based on the rates observed so far) that 50% of newly recruited patients observed for 12 months would contribute a primary outcome event, we calculated that another 174 patients would be sufficient to achieve the remaining 87 events required to complete the MOOD-HF trial.
No interim analysis was carried out for this recalculation of sample size, which was solely based on the total number of events regardless of group assignment. No changes were applied to the effect size in terms of hazard ratio or statistical power. The only change was the switch to an event-driven design including a correction of the anticipated patient number.  The following revised stopping rules were defined and included in the study protocol by protocol amendment of 6 August 2012:  The study duration will be event-driven. The target is to achieve 257 adjudicated primary outcome events.  Recruitment of 414 patients is planned at this time. However, calculation will be updated every 3 months and immediately before termination of recruitment.  Based on the observed total number of primary outcome events the Steering Committee will decide to terminate recruitment when the anticipated number of events after observation of the last patient for 12 months is at least 257.  The preceding rule that 700 patients need to be recruited in the MOOD-HF trial is herewith obsolete.  The last patient will be observed for 12 months. If the target of 257 events is not reached by this time, observation will continued until 257 events have occurred, but no longer than 24 months per patient.  When 257 events have occurred, the final visit will be scheduled within 2 weeks for all patients still under observation.
Echocardiography
Serial echocardiographic imaging was accomplished within the frame of routine patient care in all trial centers, but examinations followed a pre-specified acquisition protocol, and were performed by experienced technicians based on recommendations of the American Society and the European Association of Echocardiography. Echo technicians were unaware of patients' randomization status. The left ventricular end-diastolic diameter was measured perpendicularly to the main axis of the left ventricular chamber at the mitral chordae level in the parasternal long axis view. 6 The LVEF was derived from apical two-and fourchamber views using Simpson's biplane or single plane method. 7 Particular care was taken to precisely reproduce the cross sections in serial examinations, on which previous assessments were based, and to always use the same method for the measurements.
PHQ-9 screening cut-off values
Various cut-off values are being used in the literature. We initially chose the cut-off of >11, because own research ongoing at that time had demonstrated that, even after multivariable adjustment, this sum-score is associated with impaired survival in patients with heart failure (in contrast with values ranging from 9 to 11). 8 For that research, we had based our decision for this cut-off based on a publication of Löwe et al, who recommended a cut-off of ≥12 because in their work it yielded "a balanced trade-off between sensitivity and specificity", achieving the highest Youden Index (sensitivity + specificity -1). 9 Several authors, e.g. Kendrick et al, 10 found better diagnostic performance using cut-off values of 11 and 12 compared with the more commonly used value of 10, thus confirming the appropriateness of our choice. We changed to the cut-off value of 9 because, despite intensive efforts, our screening and, in particular, recruitment rates remained relatively low and we wanted to increase the number of patients undergoing SCID. Meta-analysis demonstrated more recently that that the PHQ-9 has acceptable diagnostic properties at a range of cut-off scores (i.e. from 8 to 11), with no significant differences in sensitivity or specificity at a cut-off value of 10 compared with other cut-off scores within the 8-11 range. 11
Determination of escitalopram serum levels
Escitalopram serum concentrations were determined by analysis of serial biomaterial samples. Samples were collected in the morning before the first study drug intake to measure trough levels. Serum was obtained by centrifugation at 1,800G for 10 minutes, and immediately stored at -80 o C for later analysis. For the purpose of this analysis, "Remission/marked improvement" in depression was defined as a MADRS sum-score of ≤12 or a decrease in the MADRS sum-score of ≥10 points; 86 patients in the escitalopram group and 68 in the placebo group were included in this category. Patients not fulfilling these criteria (48 in the escitalopram group and 56 in the placebo group) were allocated to the "no/small improvement group". No significant treatment effects with escitalopram vs. placebo were found in either subgroup (see HRs displayed in the figure panels).
In Cox regression with the two factors "treatment" and "6-week change in depression" and their interaction, the interaction term was not significant (which means that the hazard ratios shown in both panels of the figure were not significantly different from each other). In Cox regression with two factors without interaction, hazard ratio values (95% confidence interval [CI]) were 1.23 (0.90-1.70), p=0.20 for escitalopram versus placebo and 1.18 (0.86-1.62), p=0.32 for the remission/marked improvement group versus the no/small improvement group. Patients reaching an endpoint or dropping out before the 6-week assessment (46 patients in the escitalopram group and 55 in the placebo group) or not undergoing MADRS at 6 weeks (5 escitalopram recipients and 8 placebo recipients) were not included in this analysis. Abbreviations: NYHA, New York Heart Association; PHQ-9, Nine-item Patient Health Questionnaire; SCID, Structured Clinical Interview; SD, standard deviation. *n=2873 patients who qualified for the SCID based on PHQ-9 screening results. There were 2100 patients (PHQ-9 sum score 9-11/12 points: n=693/1407) who did not undergo SCID, and n=773 patients (PHQ-9 sum score 9-11/12 points: n=201/572), who underwent SCID. † This table displays data obtained when patients underwent PHQ-9 screening, and documented on the PHQ-9 form. Ethics Committees approved analysis of this screening information (age, sex, NYHA class, history of depression and PHQ-9 sum-score) without informed consent of the patients but requested that their identity be untraceable. Therefore, monitoring of these data was not permitted, and the screening data of 67 (9%) of the patients, who underwent the SCID interview, could not be matched to the SCID results. For the same reason, we did not record whether patients did not undergo SCID because of exclusion criteria, or because they refused the SCID or participation in the study. **Attendees at heart failure outpatient clinics not qualifying for SCID on a first PHQ-9 screening were eligible for repeat evaluation during a later routine follow-up visit.
© 2016 American Medical Association. All rights reserved. *Each item of the PHQ-9 yields a score of 0-3 resulting in an overall score from 0-27, with higher values indicating more severe depression. Usual cutoff points are: 0-5, normal; 6-10, mild depression; 11-15, moderate depression; 16-20, moderately severe depression; >20, severe depression. Compared with SCID and using DSM-IV diagnostic criteria, a sum-score of >9 had a sensitivity (specificity) of 88% (88%) for the diagnosis of major depressive disorder (likelihood ratio 7.1). Corresponding values for a sum-score >11 were 83% (92%), likelihood ratio 10.2. 13 In a previous study, an effect size of PHQ-9 change scores of -1.33 for improved depression status was reported (effect size = measurement1measurement 2/standard deviation of measurement 1). 13 Abbreviations: ANCOVA, analysis of covariance; CI, confidence interval; SD, standard deviation. *P-values were computed by ordinal logistic regression, including baseline NYHA class as co-factor. † The differences between groups in changes from baseline, their 95% CI and p-values were computed by analysis of covariance, including the baseline values as covariate. Note that the ANCOVA estimates adjust for the baseline values and are, therefore, not equal to the simple differences of changes within groups. ‡ The differences between groups in changes from baseline, their 95% CI and p-values were computed by analysis of covariance, including the baseline values as covariate. Computations of changes within groups and differences between groups were carried out with logarithmic NT-proBNP values. Geometric mean ratios within and between groups were obtained applying the exponential function to the respective differences on the logarithmic scale. Ratios <1 within groups indicate lowering of NT-proBNP. Ratios >1 between groups indicate more favorable changes in the placebo group. >10-20 bpm 21 (15) 21 (10) >20-30 bpm 14 (10) 10 (7) >30 bpm 5 (4) 7 (5) Abbreviations: bpm, beats/minute; GFR, glomerular filtration rate; QTc (Bazett), corrected QT time according to Bazett's formula (QT time in milliseconds divided by the square root of the duration of the R-R interval in seconds); SD, standard deviation. *Maximum increase or decrease refers to the largest change from baseline observed at any follow-up visit. † P-values from Fisher's exact test. ‡ P-values were computed from test for Kendall's tau. § P-values for maximum changes were computed from analysis of covariance, including the baseline value as covariate and adjusting for number of follow-up measurements as a co-factor. Percentages given in parentheses refer to the number of randomized patients. The table does not include hospitalization events for non-cardiovascular reasons classified as pre-planned by the blinded independent endpoint adjudication committee. Adjudication performed by the independent blinded endpoint committee was also used for the categorization of other hospitalization events. Visits to an emergency room, which did not result in an overnight stay in hospital, and which therefore did not contribute to the hospitalization endpoint, were classified as a serious adverse event. Classification of emergency room visits and of other serious adverse events into categories was carried out by a physician with special training in heart failure, who was unaware of patients' treatment allocation. † P-values were computed by ordinal (number of events) or binary (patients with event) logistic regression, adjusting for time alive and under observation in the study, which was included as a covariate. ‡ One suicide occurred in each group.
